Fast track approval process for “breakthrough” drugs proposed in the U.S.

Some experimental drugs that show a big effect early in development for treating serious or life-threatening diseases could soon get a faster and cheaper path to U.S. approval, under a proposal likely to become law this year.

Soon U.S. Food and Drug Administration would be able to label such treatments as “breakthrough” therapies, and work with companies to speed up clinical trials, for example by testing the drugs for a shorter time or enrolling fewer patients. The FDA said it supports the proposal, which is included in both versions of an FDA “must-pass” funding bill currently working its way through Congress and set to be passed by the end of the summer.

This would support President Barack Obama's aim to foster innovation as a means of spurring job creation, and may pacify some critics who say the FDA lags European countries in approving new medicines or medical devices.

Dr. Janet Woodcock, head of the FDA's drugs center, has said the FDA needs more flexibility to bypass “business as usual” when it sees unexpected effects, or when a new medicine can greatly help patients. “What happens when you have a breakthrough drug that shows an effect that's never been seen before?” she told reporters in March, discussing the proposal. “If we'd done business as usual during the AIDS epidemic, we would have never controlled that epidemic,” Woodcock said. During a spike in new cases of AIDS in the early 1990s, the FDA created an “accelerated approval” process to get new AIDS drugs to the market more quickly by allowing companies to show indirect measures of how the drug helped people.

Jeff Allen, executive director of Friends of Cancer Research, said the time was right for another avenue to speed innovative treatments to patients. Allen said new understanding of human biology and of diseases meant companies could create more effective drugs, but with fewer side effects, because they would be more targeted to specific patients or disease types.

He cited examples like Roche Holding AG's skin cancer drug Zelboraf, approved last year. He said people taking the pill were 63 percent less likely to die from melanoma than people on standard chemotherapy. There is also Pfizer Inc's targeted lung cancer drug Xalkori, which could shrink or eliminate tumors in 10 to 12 months for people with a specific genetic mutation.

“The most promising drugs show an effect early,” Allen said. “(But) there's a mentality among drug developers or FDA reviewers that you have to go through this multi-step approach” to get a drug to market. “We're hoping to encourage getting away from that,” he said.

Allen added that the FDA would retain its power to require companies to do post-approval studies, or withdraw drugs from the market if initial evidence of benefit was not shown in follow-up trials.

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2020, April 03). Fast track approval process for “breakthrough” drugs proposed in the U.S.. News-Medical. Retrieved on September 22, 2023 from

  • MLA

    Mandal, Ananya. "Fast track approval process for “breakthrough” drugs proposed in the U.S.". News-Medical. 22 September 2023. <>.

  • Chicago

    Mandal, Ananya. "Fast track approval process for “breakthrough” drugs proposed in the U.S.". News-Medical. (accessed September 22, 2023).

  • Harvard

    Mandal, Ananya. 2020. Fast track approval process for “breakthrough” drugs proposed in the U.S.. News-Medical, viewed 22 September 2023,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Unlocking the secret drivers of deadly pancreatic cancer: New target offers hope for treatment